Board and Senior Mangement

Vagif Soultanov, DSc (Hon), PhD
Executive Chairman
Vagif Soultanov is the principal founder of Solagran and led the Bioeffectives® research team in St Petersburg in the 1980s. He has doctoral qualifications in both organic chemistry and biochemistry, and is a registered medical practitioner in Russia. He first came to Australia in 1990 to work with the CSIRO Division of Forest Products as part of an inter-governmental scientific exchange program. He has published over 60 scientific papers in Russia and internationally and holds a number of patents.

Dr Ian Nisbet
Non-Executive Director and Chairman Designate
Dr Nisbet joined the Solagran Board in October 2014 and has over 30 years of drug development, business development and management experience at executive and director/Chair level in the Australian and international biotechnology sector. Dr Nisbet currently serves as Chairman or non-executive director for several Australian biotech firms and has Australian and international CEO and senior management experience. He also has a part-time role as Deputy Director (Commercialisation) at the Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland. Subject to the achievement of certain milestones by the company, Dr Nisbet will assume the role of Chairman.
Alexander Kurganov
Graduate: heat and power engineering, Tomsk State Polytechnic University
Alexander Kurganov is General Director of SibEx Limited based in Tomsk Siberia, 85% owned subsidiary of Solagran, Australia. He has been a lecturer in science at the Tomsk Polytechnic University and has 5 patents (Russian Federation) and 21 publications. He directed the construction of the world’s first facility to produce polyprenols from conifer species.
Dr Darren Schliebs
Chief Executive Officer
Dr Schliebs joined Solagran in July 2013 and is an experienced senior executive who has qualifications in both business (MBA) and science (PhD). Dr Schliebs’s senior management experience includes start-up biotechnology / healthcare companies (Alchemia Limited and Progen Pharmaceuticals) to billion-dollar revenue (CSR Limited), and most recently reported to the board and CEO of a leading Australian complementary medicine and dietary supplement company Integria Healthcare in a business transformation role. Dr Schliebs has also published several articles in the scientific and trade literature and is an author of a granted patent.